Provided by Tiger Trade Technology Pte. Ltd.

OKYO PHARMA LTD

1.39
-0.0200-1.42%
Volume:27.50K
Turnover:37.85K
Market Cap:72.95M
PE:-5.79
High:1.46
Open:1.43
Low:1.35
Close:1.41
52wk High:3.20
52wk Low:1.26
Shares:52.48M
Float Shares:28.04M
Volume Ratio:0.79
T/O Rate:0.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2400
EPS(LYR):-0.2400
ROE:-263.78%
ROA:-43.09%
PB:5.91
PE(LYR):-5.79

Loading ...

Analyst Reaffirms Buy on OKYO as Urcosimod Enters Pivotal Phase 3; $5 Price Target Maintained

TIPRANKS
·
Oct 07

OKYO Pharma Enrolls First Patients in Phase 3 Neptune Trial of Urcosimod for Neuropathic Corneal Pain

Reuters
·
Oct 06

OKYO Pharma to Present at Eyecelerator Ophthalmic Conference

Reuters
·
Sep 29

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

GlobeNewswire
·
Sep 09

OKYO Pharma Joins Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Sep 08

Piper Sandler Sticks to Its Buy Rating for OKYO Pharma Limited Sponsored ADR (OKYO)

TIPRANKS
·
Aug 27

OKYO Pharma Files Form 3 for Chief Scientific Officer Rajkumar V. Patil

Reuters
·
Jul 30

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

GlobeNewswire
·
Jul 28

OKYO Pharma Joins BTIG Biotechnology Conference 2026

Reuters
·
Jul 27

OKYO Pharma (NASDAQ:OKYO) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
Jul 27

OKYO Pharma Director Ups Stake Ahead of Planned Phase 3 Neuropathic Corneal Pain Trial

TIPRANKS
·
Jul 24

Okyo Pharma director John Brancaccio acquires 5,000 shares at $1.38

TIPRANKS
·
Jul 24

OKYO Pharma Director Brancaccio Raises Stake to 35,201 Shares After $1.48 Purchase

Reuters
·
Jul 24

Okyo Pharma says Chairman Gabriele Cerrone buys 22,500 shares at $1.45/share

TIPRANKS
·
Jul 23

OKYO Pharma Executive Boosts Shareholding Ahead of Planned Phase 3 NCP Trial

TIPRANKS
·
Jul 22

OKYO Pharma CDO Jacob Lifts Stake to 112,420 Shares with 3,500-share Buy at $1.4

Reuters
·
Jul 22

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

GlobeNewswire
·
Jul 22

OKYO Pharma to Present Ophthalmology Pipeline Ahead of Phase 3 Urcosimod Trial

TIPRANKS
·
Jul 21

Okyo Pharma Says Chairman Gabriele Cerrone Boosts Stake to 20.5%

MT Newswires Live
·
Jul 21

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

GlobeNewswire
·
Jul 21